Tumor Necrosis Factor-α Inhibitor Use Is Not Associated with Lipid Changes in Rheumatoid Arthritis

被引：4

作者：

Bili, Androniki ^{[1
]}

Morris, Stephanie J. ^{[1
]}

Sartorius, Jennifer A. ^{[1
]}

Kirchner, H. Les ^{[1
]}

Antohe, Jana L. ^{[1
]}

Dancea, Sorina ^{[1
]}

Wasko, Mary Chester ^{[1
]}

机构：

[1] Geisinger Hlth Syst, Dept Rheumatol, Danville, PA 17822 USA

来源：

JOURNAL OF RHEUMATOLOGY | 2012年 / 39卷 / 05期

关键词：

RHEUMATOID ARTHRITIS; LIPIDS; TUMOR NECROSIS FACTOR-alpha INHIBITORS; INFLIXIMAB TREATMENT; INSULIN-RESISTANCE; PROFILE; THERAPY; PATTERNS;

D O I：

10.3899/jrheum.111093

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To determine the association of use of tumor necrosis factor-alpha (TNF-alpha) inhibitors with differences in lipid levels in patients with rheumatoid arthritis (RA). Methods. We studied 807 patients with incident RA to compare differences in lipid levels in TNF-alpha inhibitor users versus nonusers, with adjustment for relevant covariables. Results. TNF-alpha inhibitor use was not associated with differences in levels of low-density lipoprotein (LDL), high-density lipoprotein (HDL), total cholesterol (TC), triglycerides, LDL:HDL, or TC:HDL compared to nonusers. Conclusion. Use of TNF-alpha inhibitor was not associated with differences in lipid levels in patients with RA. (First Release April 1 2012; J Rheumatol 2012;39:946-8; doi:10.3899/jrheum.111093)

引用

页码：946 / 948

页数：3

共 50 条

[31] Anti- and non-tumor necrosis factor-α-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis [J].

Wang, Chrong-Reen ;

Tsai, Hung-Wen .

WORLD JOURNAL OF DIABETES, 2021, 12 (03) :238-260

[32] Risk of Significant Infection in Rheumatoid Arthritis Patients Switching Anti-Tumor Necrosis Factor-α Drugs [J].

Bao-Anh Nguyen-Khoa ;

Goehring, Earl L., Jr. ;

Alexander, Kimberly A. ;

Dong, Wei ;

Napalkov, Pavel ;

Jones, Judith K. .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2012, 42 (02) :119-126

[33] Inhibitors of tumor necrosis factor for rheumatoid arthritis [J].

Moreland, LW .

JOURNAL OF RHEUMATOLOGY, 1999, 26 :7-15

[34] Polymorphisms in the 5′-flanking region of tumor necrosis factor-α gene in patients with rheumatoid arthritis [J].

Seki, N ;

Kamizono, S ;

Yamada, A ;

Higuchi, T ;

Matsumoto, H ;

Niiya, F ;

Kimura, A ;

Tsuchiya, K ;

Suzuki, R ;

Date, Y ;

Tomita, T ;

Itoh, K ;

Ochi, T .

TISSUE ANTIGENS, 1999, 54 (02) :194-197

[35] Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis. [J].

Mugnier, B ;

Bouvenot, G .

REVUE DE MEDECINE INTERNE, 2000, 21 (10) :854-862

[36] Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factor-α blockade [J].

Ingegnoli, Francesca ;

Fantini, Flavio ;

Favalli, Ennio Giulio ;

Soldi, Amedeo ;

Griffini, Samantha ;

Galbiati, Valentina ;

Meroni, Pier Luigi ;

Cugno, Massimo .

JOURNAL OF AUTOIMMUNITY, 2008, 31 (02) :175-179

[37] Tumor necrosis factor-α gene polymorphism in severe and mild-moderate rheumatoid arthritis [J].

Fabris, M ;

Di Poi, E ;

D'Elia, A ;

Damante, G ;

Sinigaglia, L ;

Ferraccioli, G .

JOURNAL OF RHEUMATOLOGY, 2002, 29 (01) :29-33

[38] Lipid Paradox in Rheumatoid Arthritis: Changes With Rheumatoid Arthritis Therapies [J].

Urruela, Matxalen Amezaga ;

Suarez-Almazor, Maria E. .

CURRENT RHEUMATOLOGY REPORTS, 2012, 14 (05) :428-437

[39] Lipid Paradox in Rheumatoid Arthritis: Changes With Rheumatoid Arthritis Therapies [J].

Matxalen Amezaga Urruela ;

Maria E. Suarez-Almazor .

Current Rheumatology Reports, 2012, 14 :428-437

[40] Targeting cytokines beyond tumor necrosis factor-α and interleukin-1 in rheumatoid arthritis [J].

McInnes I.B. ;

Gracie J.A. .

Current Pain and Headache Reports, 2005, 9 (6) :405-411

← 1 2 3 4 5 →